Treatment of hepatitis B virus-infected patients: Utility of therapeutic recommendations in developing countries

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 10, 2009, Pages 1605-1614

  Akbar, Sheikh Mohammad Fazle ^a,b   Hiasa, Yoichi ^b   Mishiro, Shunji ^a   Onji, Morikazu ^b  

^a Shinagawa ku   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Developed countries; Developing countries; HBV; Treatment guidelines

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG EFFECT; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEPATITIS B; HUMAN; NONHUMAN; PRACTICE GUIDELINE; REVIEW; SEROCONVERSION; TREATMENT RESPONSE; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DEVELOPING COUNTRIES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GUIDELINE ADHERENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; PRACTICE GUIDELINES AS TOPIC; SOCIOECONOMIC FACTORS;

EID: 67650463293     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903005579     Document Type: Review

References (77)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-1129 (Pubitemid 38298992)
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745
3. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-1683
4. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47-58
5. Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005;352:2743-2746
6. Singh NA, Reau N. Management of hepatitis B virus. J Antimicrob Chemother 2008;62:224-228
7. Ferir G, Kaptein S, Neyts J, et al. Antiviral treatment of chronic hepatitis B virus infections; the past, the present and the future. Rev Med Virol 2008;18:19-34
8. Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol 2008;23:1182-1192
9. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003;51:761-785 (Pubitemid 36503410)
10. Craxi A, Antonucci G, Camma C. Ttreament options in HBV. J Hepatol 2006;44:S77-83
11. Mahoney FJ. Update of diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-366 (Pubitemid 29196857)
12. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002;2:43-50
13. Pungparong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007;82:967-975 (Pubitemid 47206372)
14. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000: summary of a workshop. Gastroenterology 2001;120:1828-1853
15. European Association for the Study of the Liver. EASL clinical practice guidelines; Management of chronic hepatitis B. J Hepatol 2009;50:227-242
16. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539
17. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007;85:16-23
18. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virological monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008;134:405-415
19. Perrillo RP, Gish RG, Peters M, et al. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol 2006;4:233-248
20. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;22:262-283
21. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341
22. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-141 (Pubitemid 43668255)
23. Viola L, Harrison I, Coleman J, et al. Natural history of liver disease in chronic hepatitis B surface antigen carriers: survey of 100 patients from Great Britain. Lancet 1981;ii:1156-1159
24. Liaw Y, Chu C, Su I, et al. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-219
25. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986;6:167-172
26. Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol 2000;12:403-408
27. Perrillo RP. Therapy of hepatitis B -viral suppression or eradication? Hepatology 2006;43:S182-93
28. Papatheodoridis GV, Hadziyannis SJ. Current management of chronic hepatitis B. Aliment Pharmacol Ther 2004;19:25-37
29. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-81
30. Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995;1:7-36
31. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liv Int 2005;25:1097-1107 (Pubitemid 41782551)
32. Iser DM, Sasadeusz JJ. Current treatment of HIV/hepatitis B virus coinfection. J Gastroenterol Hepatol 2008;23:699-706
33. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A metaanalysis. Ann Intern Med 1993;119:312-323
34. Perillo R, Schiff E, Davis G, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301 (Pubitemid 20237094)
35. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-634
36. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129
37. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695 (Pubitemid 41007823)
38. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217 (Pubitemid 39296307)
39. Cooksley WG, Piratvisuth T, Lee SD, et al. Pegylated alpha-2a (40KDa): an evidence in the treatment of hepatitis B e antigen-positive chronic hepatitis. J Viral Hepat 2003;36:298-305 (Pubitemid 36801917)
40. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531 (Pubitemid 39315319)
41. Buti M, Cotrina M, Jardi R, et al. Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B. J Viral Hepat 2001;8:270-275 (Pubitemid 32673738)
42. de Franchis R, Hadengue A, Lau G, et al. ASL International Consensus Conference on Hepatitis B, Consensus statement (long version), 13-14 September, 2002 Geneva, Switzerland. J Hepatol 2003;39(Suppl 1):S3-25
43. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263 (Pubitemid 29489740)
44. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B and antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816 (Pubitemid 36245757)
45. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807 (Pubitemid 36245756)
46. Wolters LM, Hansen BE, Niesters HG, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002;37:137-144 (Pubitemid 34713065)
47. Lai CL, Leung N, Tei EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen positive chronic hepatitis B. Gastroenterology 2005;129:526-536
48. Lai C-L, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588 (Pubitemid 350294224)
49. Marcellin P, Heathcote J, Buti M, et al. Tenofovir disoproxil versus adefovir dipivoxil for chronic hepatitis B. N Eng J Med 2008;359:2442-2455
50. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425
51. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005;43:60-66 (Pubitemid 40805273)
52. Fung SK, Wong F, Hussain M, et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepatol 2004;11:432-438 (Pubitemid 39336224)
53. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020 (Pubitemid 43357805)
54. Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir Chem Chemother 2004;15:299-305
55. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Res 2004;64:1-5 (Pubitemid 39307089)
56. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696
57. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722
58. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297
59. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-1398
60. Villet S, Billioud G, Pichoud C, et al. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009;136:168-176
61. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-1665
62. Delaney WE 4th, Borroto-Esoda K. Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol 2008;8:532-540
63. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for the treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049
64. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-911
65. Baldick CJ, Eggers BJ, Fang J, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008;48:895-902 (Pubitemid 351702731)
66. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507
67. Kumar M, Sarin SK. Systemic review: combination therapies for treatment-naïve chronic hepatitis B. Aliment Pharmacol Ther 2008;27:1187-1209 (Pubitemid 351697280)
68. Schalm SW, Heathcote J, Ciancira J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized- controlled trial. Gut 2000;46:562-568
69. Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003;21:4626-4649 (Pubitemid 37329857)
70. Pol S. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Biomed Pharmacother 1995;49:105-109
71. Sprengers D, Janssen HL, Kwekkeboom J, et al. In vivo immunization following virus suppression: a novel approach for inducing immune control in chronic hepatitis B. J Viral Hepatol 2003;10:7-9
72. Akbar SM, Furukawa S, Horiike N, et al. Vaccine therapy for hepatitis B virus carrier. Curr Drug Targets Infect Disord 2004;4:93-101
73. Horiike N, Akbar SM, Michitaka K, et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005;32:156-161
74. Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005;19:17-26 (Pubitemid 40204344)
75. Shamiliyan TA, MacDonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis B; A systemic review for a national institute of health consensus development conference. Ann Intern Med 2009;150:111-124
76. Artan R. Lamivudine monotherapy in children with immune-tolerant chronic hepatitis B. J Chemother 2005;17:198-202 (Pubitemid 40732880)
77. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an international AIDS society-USA panel. Curr Infect Dis 2008;47:266-285